BACKGROUND: Recent case reports have suggested that some asymptomatic HIV-infected individuals can develop CNS disturbances despite intact immunologic functioning and long-term suppression of plasma HIV concentrations to undetectable levels. This possibility has not yet been systematically studied longitudinally. METHODS: Using longitudinal data from the Multicenter AIDS Cohort Study, we investigated neuropsychological performance in long-term asymptomatic HIV-infected men who have sex with men. Performance over a 5-year period on the Symbol Digit Modalities test and the Trail Making Tests were compared in three HIV-positive asymptomatic groups [defined as 1) highly active antiretroviral therapy (HAART) treated with undetectable viral loads (n = 83), 2) AIDS-free for more than 15 years without HAART (n = 29), and 3) absence of clinical AIDS or CD4(+) lymphocyte count below 200 cells/muL at the beginning and end of the study period (n = 233)] and in HIV-negative controls (n = 237). Data were analyzed using linear mixed models and proportional odds logistic regression modeling with generalized estimating equations. RESULTS: There was no evidence of performance differences or performance declines over the 5-year period of study in any of the three long-term asymptomatic groups as compared with the HIV-negative group in the Symbol Digit Modalities test or the Trail Making Tests. Performance decrements were, however, observed with increasing age in each of the tests administered, demonstrating that performance declines could be detected by these methods. CONCLUSIONS: Regardless of how long-term asymptomatic status was defined immunologically or virologically, neuropsychological test performances remained stable. These findings suggest that psychomotor speed is preserved over many years in HIV-infected individuals with controlled HIV viremia.
BACKGROUND: Recent case reports have suggested that some asymptomatic HIV-infected individuals can develop CNS disturbances despite intact immunologic functioning and long-term suppression of plasma HIV concentrations to undetectable levels. This possibility has not yet been systematically studied longitudinally. METHODS: Using longitudinal data from the Multicenter AIDS Cohort Study, we investigated neuropsychological performance in long-term asymptomatic HIV-infectedmen who have sex with men. Performance over a 5-year period on the Symbol Digit Modalities test and the Trail Making Tests were compared in three HIV-positive asymptomatic groups [defined as 1) highly active antiretroviral therapy (HAART) treated with undetectable viral loads (n = 83), 2) AIDS-free for more than 15 years without HAART (n = 29), and 3) absence of clinical AIDS or CD4(+) lymphocyte count below 200 cells/muL at the beginning and end of the study period (n = 233)] and in HIV-negative controls (n = 237). Data were analyzed using linear mixed models and proportional odds logistic regression modeling with generalized estimating equations. RESULTS: There was no evidence of performance differences or performance declines over the 5-year period of study in any of the three long-term asymptomatic groups as compared with the HIV-negative group in the Symbol Digit Modalities test or the Trail Making Tests. Performance decrements were, however, observed with increasing age in each of the tests administered, demonstrating that performance declines could be detected by these methods. CONCLUSIONS: Regardless of how long-term asymptomatic status was defined immunologically or virologically, neuropsychological test performances remained stable. These findings suggest that psychomotor speed is preserved over many years in HIV-infected individuals with controlled HIV viremia.
Authors: Ned Sacktor; Richard L Skolasky; Christopher Cox; Ola Selnes; James T Becker; Bruce Cohen; Eileen Martin; Eric N Miller Journal: J Neurovirol Date: 2010-10 Impact factor: 2.643
Authors: Howard A Crystal; Jeremy Weedon; Susan Holman; Jennifer Manly; Victor Valcour; Mardge Cohen; Kathryn Anastos; Chenglong Liu; Wendy J Mack; Elizabeth Golub; Jason Lazar; Ann Ho; Mary Jeanne Kreek; Robert C Kaplan Journal: J Neurovirol Date: 2011-10-18 Impact factor: 2.643
Authors: Andrea D Klunder; Ming-Chang Chiang; Rebecca A Dutton; Sharon E Lee; Arthur W Toga; Oscar L Lopez; Howard J Aizenstein; James T Becker; Paul M Thompson Journal: Neuroreport Date: 2008-11-19 Impact factor: 1.837
Authors: Lucette A Cysique; Scott L Letendre; Christopher Ake; Hua Jin; Donald R Franklin; Saurabh Gupta; Chuan Shi; Xin Yu; Zunyou Wu; Ian S Abramson; Igor Grant; Robert K Heaton Journal: AIDS Date: 2010-04-24 Impact factor: 4.177
Authors: Nicole M Armstrong; Pamela J Surkan; Glenn J Treisman; Ned C Sacktor; Michael R Irwin; Linda A Teplin; Ron Stall; Eileen M Martin; James T Becker; Cynthia Munro; Andrew J Levine; Lisa P Jacobson; Alison G Abraham Journal: J Neurovirol Date: 2017-04-20 Impact factor: 2.643
Authors: James T Becker; Lawrence A Kingsley; Samantha Molsberry; Sandra Reynolds; Aaron Aronow; Andrew J Levine; Eileen Martin; Eric N Miller; Cynthia A Munro; Ann Ragin; Ned Sacktor; Ola A Selnes Journal: Int J Epidemiol Date: 2014-04-24 Impact factor: 7.196
Authors: Quynh T Vo; Christopher Cox; Xiuhong Li; Lisa P Jacobson; Rosemary McKaig; Ned Sacktor; Ola A Selnes; Eileen Martin; James T Becker; Eric N Miller Journal: J Neurovirol Date: 2012-12-11 Impact factor: 2.643